XML 13 R7.htm IDEA: XBRL DOCUMENT v3.25.2
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)
$ in Thousands
Total
Common Shares
Treasury Stock
Capital in Excess of Par Value
 [1]
Accumulated Other Comprehensive Income/(Loss)
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2023 [1]   12,757,984        
Beginning balance at Dec. 31, 2023 $ 130,987 $ 1 [1]   $ 3,608,155 $ 80 $ (3,477,249)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Shares issued under equity compensation plans (in shares) [1]   35,131        
Shares issued under equity compensation plans 3     3    
Stock-based compensation 6,000     6,000    
Repurchase of common stock from Bristol-Myers Squibb (in shares) [1]   (552,307) 552,307      
Repurchase of common stock from Bristol-Myers Squibb (3,000)   $ (3,000)      
Issuance of prefunded warrant 30,000     30,000    
Comprehensive income (loss) (37,285)       (483) (36,802)
Ending balance (in shares) at Mar. 31, 2024 [1]   12,240,808        
Ending balance at Mar. 31, 2024 126,705 $ 1 [1] $ (3,000) 3,644,158 (403) (3,514,051)
Ending balance (in shares) at Mar. 31, 2024 [1]     552,307      
Beginning balance (in shares) at Dec. 31, 2023 [1]   12,757,984        
Beginning balance at Dec. 31, 2023 130,987 $ 1 [1]   3,608,155 80 (3,477,249)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Comprehensive income (loss) (89,739)          
Ending balance (in shares) at Jun. 30, 2024 [1]   12,269,903        
Ending balance at Jun. 30, 2024 79,688 $ 1 [1] $ (3,000) 3,649,595 (494) (3,566,414)
Ending balance (in shares) at Jun. 30, 2024 [1]     552,307      
Beginning balance (in shares) at Mar. 31, 2024 [1]   12,240,808        
Beginning balance at Mar. 31, 2024 126,705 $ 1 [1] $ (3,000) 3,644,158 (403) (3,514,051)
Beginning balance (in shares) at Mar. 31, 2024 [1]     552,307      
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Shares issued under equity compensation plans (in shares) [1]   29,095        
Shares issued under equity compensation plans 19     19    
Stock-based compensation 5,418     5,418    
Comprehensive income (loss) (52,454)       (91) (52,363)
Ending balance (in shares) at Jun. 30, 2024 [1]   12,269,903        
Ending balance at Jun. 30, 2024 $ 79,688 $ 1 [1] $ (3,000) 3,649,595 (494) (3,566,414)
Ending balance (in shares) at Jun. 30, 2024 [1]     552,307      
Beginning balance (in shares) at Dec. 31, 2024 12,385,001 12,385,001 [1]        
Beginning balance at Dec. 31, 2024 $ 60,737 [2] $ 1 [1] $ (3,000) 3,659,885 61 (3,596,210)
Beginning balance (in shares) at Dec. 31, 2024 552,307   552,307 [1]      
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Shares issued under equity compensation plans (in shares) [1]   21,709        
Shares issued under equity compensation plans $ 7     7    
Stock-based compensation 3,898     3,898    
Comprehensive income (loss) (50,904)       (22) (50,882)
Ending balance (in shares) at Mar. 31, 2025 [1]   12,406,710        
Ending balance at Mar. 31, 2025 $ 13,738 $ 1 [1] $ (3,000) 3,663,790 39 (3,647,092)
Ending balance (in shares) at Mar. 31, 2025 [1]     552,307      
Beginning balance (in shares) at Dec. 31, 2024 12,385,001 12,385,001 [1]        
Beginning balance at Dec. 31, 2024 $ 60,737 [2] $ 1 [1] $ (3,000) 3,659,885 61 (3,596,210)
Beginning balance (in shares) at Dec. 31, 2024 552,307   552,307 [1]      
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Comprehensive income (loss) $ (92,550)          
Ending balance (in shares) at Jun. 30, 2025 12,457,252 12,457,252 [1]        
Ending balance at Jun. 30, 2025 $ (24,211) $ 1 [1] $ (3,000) 3,667,487 (14) (3,688,685)
Ending balance (in shares) at Jun. 30, 2025 552,307   552,307 [1]      
Beginning balance (in shares) at Mar. 31, 2025 [1]   12,406,710        
Beginning balance at Mar. 31, 2025 $ 13,738 $ 1 [1] $ (3,000) 3,663,790 39 (3,647,092)
Beginning balance (in shares) at Mar. 31, 2025 [1]     552,307      
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Shares issued under equity compensation plans (in shares) [1]   50,542        
Shares issued under equity compensation plans 211     211    
Stock-based compensation 3,486     3,486    
Comprehensive income (loss) $ (41,646)       (53) (41,593)
Ending balance (in shares) at Jun. 30, 2025 12,457,252 12,457,252 [1]        
Ending balance at Jun. 30, 2025 $ (24,211) $ 1 [1] $ (3,000) $ 3,667,487 $ (14) $ (3,688,685)
Ending balance (in shares) at Jun. 30, 2025 552,307   552,307 [1]      
[1] All share and per share amounts have been retrospectively adjusted to reflect a one-for-fifteen reverse stock split (see Note 6).
[2] All share and per share amounts have been retrospectively adjusted to reflect a one-for-fifteen reverse stock split (see Note 6).